argenx SE (ARGX)

Market Cap	52.77B
Revenue (ttm)	3.68B
Net Income (ttm)	1.53B
Shares Out	61.37M
EPS (ttm)	23.27
PE Ratio	34.41
Forward PE	29.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	366,804
Open	851.52
Previous Close	847.05
Day's Range	849.53 - 863.11
52-Week Range	510.06 - 934.62
Beta	-0.11
Analysts	Strong Buy
Price Target	971.89 (+13.67%)
Earnings Date	Oct 30, 2025

About ARGX

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 18, 2017
• Employees: 1,599
• Stock Exchange: NASDAQ
• Ticker Symbol: ARGX
• Website: https://argenx.com

Analyst Summary

According to 19 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price target is $971.89, which is an increase of 13.67% from the latest price.

Price Target

$971.89

(13.67% upside)

Analyst Consensus: Strong Buy